Improvement of lenvatinib-induced nephrotic syndrome after adaptation to sorafenib in thyroid cancer: A case report

BACKGROUND: Target therapy is licensed by United States Food and Drug Administration on certain cancers. Both sorafenib and lenvatinib are tyrosine kinase inhibitor and indicated on radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). Lenvatinib is more effective in cancers'...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Che Hseuh, Chen, Kuo Tung, Lin, Yi Sheng, Hsu, Chao Yu, Ou, Yen Chuan, Tung, Min Che
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7642543/
https://www.ncbi.nlm.nih.gov/pubmed/33195657
http://dx.doi.org/10.12998/wjcc.v8.i20.4883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7642543/
https://www.ncbi.nlm.nih.gov/pubmed/33195657
http://dx.doi.org/10.12998/wjcc.v8.i20.4883

Ejemplares similares